Baudax Bio Past Earnings Performance
Past criteria checks 0/6
Baudax Bio has been growing earnings at an average annual rate of 11.3%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 52.6% per year.
Key information
11.3%
Earnings growth rate
143.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 52.6% |
| Return on equity | n/a |
| Net Margin | -4,665.2% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Baudax Bio stock down after pricing $6.2M equity offering
Aug 30Baudax Bio to get US patent linked to pain drug Anjeso
Aug 22Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M
Aug 11Cosette Pharmaceuticals appoints Rick Casten as CFO
Jul 06Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds
Sep 09A First Look At Baudax Bio
May 30Baudax Bio EPS misses by $0.08, misses on revenue
May 05Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty
Apr 26Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?
Feb 17
Baudax Bio EPS of $0.62
Nov 09Baudax Bio: Why I'm Catching This Falling Knife
Nov 03Revenue & Expenses BreakdownBeta
How Baudax Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -59 | 19 | 8 |
| 30 Jun 23 | 1 | -61 | 18 | 7 |
| 31 Mar 23 | 1 | -58 | 19 | 6 |
| 31 Dec 22 | 1 | -59 | 24 | 4 |
| 30 Sep 22 | 0 | 13 | 24 | 3 |
| 30 Jun 22 | 1 | 0 | 32 | 3 |
| 31 Mar 22 | 1 | -11 | 40 | 3 |
| 31 Dec 21 | 1 | -20 | 45 | 3 |
| 30 Sep 21 | 1 | -66 | 44 | 6 |
| 30 Jun 21 | 1 | -38 | 47 | 7 |
| 31 Mar 21 | 1 | -53 | 47 | 7 |
| 31 Dec 20 | 0 | -76 | 43 | 9 |
| 30 Sep 20 | 0 | -66 | 38 | 7 |
| 30 Jun 20 | 0 | -88 | 29 | 8 |
| 31 Mar 20 | 0 | -69 | 21 | 11 |
| 31 Dec 19 | 0 | -33 | 23 | 17 |
| 30 Sep 19 | 0 | -42 | 23 | 26 |
| 30 Jun 19 | 0 | -51 | 23 | 34 |
| 31 Mar 19 | 0 | -61 | 31 | 38 |
| 31 Dec 18 | 0 | -74 | 29 | 36 |
Quality Earnings: BXRX.Q is currently unprofitable.
Growing Profit Margin: BXRX.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BXRX.Q is unprofitable, but has reduced losses over the past 5 years at a rate of 11.3% per year.
Accelerating Growth: Unable to compare BXRX.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BXRX.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: BXRX.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.